Capstone Therapeutics Cor... (CAPS)
NASDAQ: CAPS
· Real-Time Price · USD
1.14
-0.10 (-8.06%)
At close: Aug 18, 2025, 3:59 PM
1.13
-0.44%
After-hours: Aug 18, 2025, 07:43 PM EDT
Company Description
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States.
It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism.
The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010.
Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
Capstone Therapeutics Corp.
| Country | United States |
| IPO Date | Jan 28, 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Matthew E. Lipman |
Contact Details
Address: 1275 West Washington Street Tempe, Arizona United States | |
| Website | https://www.capstonethx.com |
Stock Details
| Ticker Symbol | CAPS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000887151 |
| CUSIP Number | 14068E208 |
| ISIN Number | US14068E2081 |
| Employer ID | 86-0585310 |
| SIC Code | 5030 |
Key Executives
| Name | Position |
|---|---|
| Matthew E. Lipman | Chief Executive Officer, President, Secretary & Director |
| Edward C. Schultz | Vice President of Finance, Chief Financial Officer & Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2025 | 8-K | Current Report |
| Aug 15, 2025 | 424B3 | Filing |
| Aug 15, 2025 | 8-K | Current Report |
| Aug 15, 2025 | 10-Q | Quarterly Report |
| Aug 15, 2025 | NT 10-Q | Filing |
| Aug 14, 2025 | 424B3 | Filing |
| Aug 04, 2025 | S-1 | Filing |
| Aug 04, 2025 | 8-K | Current Report |
| Jun 30, 2025 | 8-K | Current Report |
| Jun 27, 2025 | 8-K | Current Report |